Tuberculosis vaccines: Opportunities and challenges. (Q47552546)

3 February 2018

title

Tuberculosis vaccines: Opportunities and challenges. (English)

1 reference

3 February 2018

1 reference

2

Hazel M Dockrell

1 reference

3 February 2018

Thomas G. Evans

4

object named as

Thomas G Evans

1 reference

3 February 2018

Tom H M Ottenhoff

3

object named as

Tom H M Ottenhoff

1 reference

3 February 2018

author name string

Bingdong Zhu

1

1 reference

3 February 2018

Ying Zhang

5

1 reference

3 February 2018

publication date

17 January 2018

1 reference

3 February 2018

published in

Respirology

1 reference

3 February 2018

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

cites work

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

The Achilles heel of BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

The contribution of immunology to the rational design of novel antibacterial vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Antibodies and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Mycobacterium tuberculosis produces pili during human infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Immunopathogenesis of tuberculosis and novel mechanisms of vaccine activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

TB vaccines: progress and problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Exploration of novel cellular and serological antigen biomarkers in the ORFeome of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A first dataset toward a standardized community-driven global mapping of the human immunopeptidome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Novel approaches to tuberculosis vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

The cell envelope of tubercle bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

CD1 and mycobacterial lipids activate human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

CD1b tetramers bind αβ T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A microbial glycolipid functions as a new class of target antigen for delayed-type hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Novel approaches to preclinical research and TB vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin ΔureC::hly vaccine's superior protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

The Recombinant BCG ΔureC::hly Vaccine Targets the AIM2 Inflammasome to Induce Autophagy and Inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Tuberculosis vaccines and prevention of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Increased TNF-α/IFN-γ/IL-2 and Decreased TNF-α/IFN-γ Production by Central Memory T Cells Are Associated with Protective Responses against Bovine Tuberculosis Following BCG Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Systems approach to tuberculosis vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Metabolic Phenotypes of Response to Vaccination in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Trained immunity: A program of innate immune memory in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Whole Blood Profiling of Bacillus Calmette-Guérin-Induced Trained Innate Immunity in Infants Identifies Epidermal Growth Factor, IL-6, Platelet-Derived Growth Factor-AB/BB, and Natural Killer Cell Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Personalized vaccinology: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

T-cell activation is an immune correlate of risk in BCG vaccinated infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Lipoarabinomannan-Responsive Polycytotoxic T Cells Are Associated with Protection in Human Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Animal models of cavitation in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Host genetics in granuloma formation: human-like lung pathology in mice with reciprocal genetic susceptibility to M. tuberculosis and M. avium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Animal models of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Perspectives on clinical and preclinical testing of new tuberculosis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

Pathogenesis of bovine tuberculosis: the role of experimental models of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

A New Rabbit-Skin Model to Evaluate Protective Efficacy of Tuberculosis Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13245

21 January 2018

Identifiers

DOI

10.1111/RESP.13245

1 reference

3 February 2018

PubMed ID

29341430

1 reference

3 February 2018